Literature DB >> 8792904

Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years.

A Berghöfer1, B Kossmann, B Müller-Oerlinghausen.   

Abstract

We analysed the recurrences of 86 patients with monopolar and bipolar mood and schizoaffective disorders treated with lithium over a period of 8.2 years on average in a specialized out-patient clinic. Lithium medication was discontinued by 24% of patients. Diagnosis, age and gender had no influence on the mean morbidity index. Bipolar and schizoaffective patients suffered from more severe recurrences, resulting in hospital admissions, than monopolar patients. A significant decrease in intensity of manic episodes and a significant shortening of depressive episodes was observed over a 10-year treatment period. However, the percentage of manic episodes among all episodes remained constant. There was no indication of a loss of the prophylactic effect in a subgroup of 30 patients who had been treated for a minimum of 10 years. The morbidity index also remained constant over 10 years in the whole sample. Furthermore, the mean lithium blood levels as well as the additional medication in this subgroup could be lowered in the second half of the treatment decade as compared to the initial 5 years.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8792904     DOI: 10.1111/j.1600-0447.1996.tb10659.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  7 in total

1.  Long-term lithium treatment and thyroid antibodies: a controlled study.

Authors:  Christopher Baethge; Holger Blumentritt; Anne Berghöfer; Tom Bschor; Tasha Glenn; Mazda Adli; Peter Schlattmann; Michael Bauer; Reinhard Finke
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

Review 2.  Distinctions between bipolar and unipolar depression.

Authors:  Amy K Cuellar; Sheri L Johnson; Ray Winters
Journal:  Clin Psychol Rev       Date:  2005-05

3.  The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998.

Authors:  C E Begley; J F Annegers; A C Swann; C Lewis; S Coan; W B Schnapp; L Bryant-Comstock
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder.

Authors:  Christopher Baethge; Philipp Gruschka; Michael N Smolka; Anne Berghöfer; Tom Bschor; Bruno Müller-Oerlinghausen; Michael Bauer
Journal:  J Psychiatry Neurosci       Date:  2003-09       Impact factor: 6.186

Review 5.  Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium.

Authors:  Hubertus Himmerich; Dagmar Koethe; Andreas Schuld; Alexander Yassouridis; Thomas Pollmächer
Journal:  Psychopharmacology (Berl)       Date:  2004-11-25       Impact factor: 4.530

7.  Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients.

Authors:  Anne Berghöfer; Martin Alda; Mazda Adli; Christopher Baethge; Michael Bauer; Tom Bschor; Paul Grof; Bruno Müller-Oerlinghausen; Janusz K Rybakowski; Alexandra Suwalska; Andrea Pfennig
Journal:  Int J Bipolar Disord       Date:  2013-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.